Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Description:

For complete information, please view the study on clinicaltrials.gov.

This study is being done in collaboration with Cincinnati Children's Hospital.

Medication Under Study:
Etinostat

Full IRB Study Title:
ADVL1513: A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

IRB Study ID:
1042403-1

If you are interested in this study or have questions about your child's eligibility, please contact: Rebecca D. Considine Research Institute, 330-543-5012


Lead Principal Investigator:

Photo
Steven Kuerbitz, MD
Director, Divisional Research and Stem Cell Transplantation


Bookmark and Share

Developments Developments
Sign up for enewsletter
Get involved Get involved
Discover ways to support Akron Children's
    Contact Us

    330-543-5012

    E-mail

    find a location
    Find a location Type the first 3-5 letters of a specialty, service or location:
    Or, view: a map, a list of all locations, locations by city or locations near me.
    find a doctor
    Find a doctor Type the first 3-5 letters of the name, location or specialty:
    Or, view a list of all doctors by name, location and specialty.